In their Spine Precision Partnership™, the companies will join forces in advancing their proprietary technologies with the objective of creating solutions which improve operating room (OR) workflow efficiency and provide increased precision in the delivery of minimally disruptive spine surgery technologies. The first step in the Spine Precision Partnership is to integrate NuVasive’s Pulse™ surgical automation platform with Siemens Healthineers’ Cios Spin* cutting-edge mobile 3D imaging for intra-operative quality assurance.

“Currently, a number of hospitals and healthcare systems treat patients undergoing spine surgery through often cost-intensive, intra-operative CT scans with a general navigation system with limited utilization in spine surgery cases. The combination of NuVasive’s Pulse system and the Siemens Healthineers’ next-generation advanced imaging technology provides a compelling offering for hospitals and surgeons who require a scalable, cost-efficient technology that maximizes OR workflow efficiency and significantly improves visualization for spine surgery,” said Gregory T. Lucier, chairman and chief executive officer of NuVasive. “We firmly believe that this combined offering will enable advanced clinical benefits driving superior patient outcomes, delivered through greatly improved visualization of the anatomy promoting successful anatomical access and spinal implant placement.”

“We at Siemens Healthineers are excited to work with NuVasive to develop intra-operative 3D-imaging and navigation tools for our advanced imaging systems that empower spine surgeons and neurosurgeons to be more precise, faster and cost efficient in the operating room. Increased workflow efficiency, better image quality, as well as predictable and reproducible results, will transform care delivery and set a new standard in spine surgery,” said Peter Seitz, head of Surgery at Siemens Healthineers.

NuVasive and Siemens Healthineers will feature the Spine Precision Partnership at the North American Spine Society 2018 Annual Meeting held September 26-29, 2018 in Los Angeles, California.

* Cios Spin from Siemens Healthineers is pending 510(k) clearance, and is not yet commercially available in the United States.

Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving patient experience and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services.

In fiscal 2017, which ended on September 30, 2017, Siemens Healthineers generated revenue of €13.7 billion and adjusted profit of €2.5 billion and has about 48,000 employees worldwide. Further information is available at www.siemens-healthineers.com.

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA® platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

This press release is available at www.healthcare.siemens.com/press-room/press-releases/PR-20180809027SHS.html.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com